Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study

Authors:
  • ISIain Stewart
    Iain Stewart
  • PYPeter Youssef
    Peter Youssef
  • SAStephen Adelstein
    Stephen Adelstein
  • DLDonna Lai
    Donna Lai
  • SHSheng Hua
    Sheng Hua
  • WSWendy Mr Stevens
    Wendy Mr Stevens
  • SPSusanna Proudman
    Susanna Proudman
  • GNGene-Siew Ngian
    Gene-Siew Ngian
  • IGIan N Glaspole
    Ian N Glaspole
  • YMYuben P Moodley
    Yuben P Moodley
  • JBJane F Bleasel
    Jane F Bleasel

Abstract
Introduction: Systemic sclerosis associated interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in SSc. Precise measures to identify SSc-ILD and assist risk-stratification are lacking. Aim: Investigate composite serum biomarker panels for SSc-ILD diagnosis. Methods: 28 biomarkers were analysed in 640 participants from two national longitudinal cohorts:259 SSc-ILD, 179 SSc-controls without ILD, 172 IPF-controls, and 30 healthy controls. A composite index was developed from biomarkers associated with fibrotic lung disease in multivariable analysis derived at empirical thresholds. Performance of the index to identify fibrotic lung disease and SSc-ILD, its association with physiology, quality of life and transplant free survival (TFS) were evaluated in derivation and validation cohorts. Biomarkers to distinguish SSc-ILD from IPF-controls were identified. Results: A composite biomarker index, comprising SP-D, Ca15-3 and ICAM-1, was strongly associated with SSc-ILD diagnosis, independent of age, sex, smoking and lung function (index=3: pooled adj. OR 12·72, p<0·001). The index strengthened the performance of individual biomarkers for SSc-ILD identification. In SSc patients, a higher biomarker index was associated with worse baseline disease severity (index=3 relative to index=0: adjusted absolute change in FVC% –17·84% and DLCO% –20·16%, both p<0·001) and TFS (index=3: pooled adj. HR 2·27, p=0·043). TGF-b1 and CXCL-10 discriminated SSc-ILD from IPF. Conclusion: A composite serum biomarker index, comprising SP-D, Ca15-3, ICAM-1, may improve the identification and severity assessment of SSc-ILD at baseline.